Hemorrhagic fever viruses as biological weapons: medical and public health management.
暂无分享,去创建一个
Philip K. Russell | J. Hughes | M. Ascher | M. Hamburg | P. Jahrling | G. Nabel | T. O'Toole | T. Inglesby | J. Breman | T. Perl | M. Osterholm | C. Peters | D. Henderson | T. Ksiazek | J. Bartlett | E. Eitzen | J. Hauer | P. Russell | K. Tonat | L. Borio | A. Meyerhoff | A. Schmaljohn | Richard T. Johnson | S. Lillibridge | M. Layton | K. Johnson | Gigi Kwik | J. Hughes
[1] J. E. Bennett,et al. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases , 2014 .
[2] Samuel D. Uretsky,et al. Germs: Biological Weapons and America's Secret War , 2002 .
[3] H. Zeller,et al. Shortage of vaccines during a yellow fever outbreak in Guinea , 2001, The Lancet.
[4] T. Monath,et al. Yellow fever: an update. , 2001, The Lancet. Infectious diseases.
[5] Jerome Hauer,et al. Tularemia as a biological weapon , 2001 .
[6] Philip K. Russell,et al. Tularemia as a biological weapon: medical and public health management. , 2001, JAMA.
[7] R. Ahmed,et al. Passive Transfer of Antibodies Protects Immunocompetent and Immunodeficient Mice against Lethal Ebola Virus Infection without Complete Inhibition of Viral Replication , 2001, Journal of Virology.
[8] Philip K. Russell,et al. Botulinum toxin as a biological weapon: medical and public health management. , 2001, JAMA.
[9] T. Solomon,et al. Dengue and other emerging flaviviruses. , 2001, The Journal of infection.
[10] A. Sanchez,et al. Development of a preventive vaccine for Ebola virus infection in primates , 2000, Nature.
[11] R. Charrel,et al. Fatal illnesses associated with a new world arenavirus--California, 1999-2000. , 2000, MMWR. Morbidity and mortality weekly report.
[12] L. Hutwagner,et al. Effective Vaccine for Lassa Fever , 2000, Journal of Virology.
[13] J. P. Chen,et al. Hemorrhagic fever virus-induced changes in hemostasis and vascular biology , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[14] P. Klenerman,et al. Additive Effect of Neutralizing Antibody and Antiviral Drug Treatment in Preventing Virus Escape and Persistence , 2000, Journal of Virology.
[15] Gina Pugliese,et al. Plague as Biological Weapon , 2000, Infection Control & Hospital Epidemiology.
[16] A. K. Hansen,et al. Marburg and Ebola virus infections in laboratory non-human primates: a literature review. , 2000, Comparative medicine.
[17] B. Cunha. Tickborne Infectious Diseases: Diagnosis and Management , 2000 .
[18] R. Swanepoel,et al. Unexpected Ebola virus in a tertiary setting: Clinical and epidemiologic aspects , 2000, Critical care medicine.
[19] S. So,et al. Intravenous ribavirin therapy for adenovirus pneumonia , 2000, Pediatric pulmonology.
[20] M. Hussein,et al. An epizootic of Rift Valley fever in Egypt in 1997. , 1999, Revue scientifique et technique.
[21] C. Peters,et al. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. , 1999, Vaccine.
[22] Philip K. Russell,et al. Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. , 1999, JAMA.
[23] Philip K. Russell,et al. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. , 1999, JAMA.
[24] S. Edberg,et al. Management of a Sabiá Virus-Infected Patient in a US Hospital , 1999, Infection Control & Hospital Epidemiology.
[25] T. Ksiazek,et al. Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: risk factors for patients without a reported exposure. , 1999, The Journal of infectious diseases.
[26] R. Colebunders,et al. Ebola outbreak in Kikwit, Democratic Republic of the Congo: discovery and control measures. , 1999, The Journal of infectious diseases.
[27] J Bertolli,et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit. , 1999, The Journal of infectious diseases.
[28] S. Dowell,et al. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit. , 1999, The Journal of infectious diseases.
[29] Ali S Khan,et al. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidémies à Kikwit. , 1999, The Journal of infectious diseases.
[30] E. Ryabchikova,et al. An analysis of features of pathogenesis in two animal models of Ebola virus infection. , 1999, The Journal of infectious diseases.
[31] P. Formenty,et al. Human infection due to Ebola virus, subtype Côte d'Ivoire: clinical and biologic presentation. , 1999, The Journal of infectious diseases.
[32] R. Colebunders,et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. , 1999, The Journal of infectious diseases.
[33] P. Rollin,et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. , 1999, The Journal of infectious diseases.
[34] A. Sanchez,et al. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit. , 1999, The Journal of infectious diseases.
[35] R. Colebunders,et al. Organization of patient care during the Ebola hemorrhagic fever epidemic in Kikwit, Democratic Republic of the Congo, 1995. , 1999, The Journal of infectious diseases.
[36] A. Sanchez,et al. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. , 1999, The Journal of infectious diseases.
[37] J. Smith,et al. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. , 1998, Virology.
[38] P. Jahrling,et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. , 1998, Virology.
[39] D. Vlahov,et al. Tuberculosis risk in funeral home employees. , 1998, Journal of occupational and environmental medicine.
[40] B. Kay,et al. Susceptibility of selected strains of Australian mosquitoes (Diptera: Culicidae) to Rift Valley fever virus. , 1998, Journal of medical entomology.
[41] L. Harrison,et al. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. , 1998, The Journal of infectious diseases.
[42] P. Jahrling,et al. Clinical recognition and management of patients exposed to biological warfare agents. , 1997, Clinics in laboratory medicine.
[43] T. Ksiazek,et al. Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[44] K. Fennelly. Personal respiratory protection against Mycobacterium tuberculosis. , 1997, Clinics in chest medicine.
[45] E K Eck,et al. The Effect of High-Efficiency Particulate Air Respirator Design on Occupational Health: A Pilot Study Balancing Risks in the Real World , 1997, Infection Control & Hospital Epidemiology.
[46] A. Vannier,et al. The effect of high-efficiency particulate air respirator design on occupational health: a pilot study balancing risks in the real world. , 1997 .
[47] S. Ostroff,et al. Perspectives in fatal epidemics. , 1996, Infectious disease clinics of North America.
[48] Sinroku Otatume,et al. Ebola haemorrhagic fever in Zaire , 1996 .
[49] P. Jahrling,et al. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. , 1996, Archives of pathology & laboratory medicine.
[50] K. Steele,et al. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory , 1995, The Lancet.
[51] P. Jahrling,et al. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. , 1995, International journal of experimental pathology.
[52] Sergeev An,et al. Certain pathogenetic characteristics of a disease in monkeys in infected with the Marburg virus by an airborne route , 1995 .
[53] K. Banerjee,et al. Field evaluation of formalin inactivated Kyasanur forest disease virus tissue culture vaccine in three districts of Karnataka state. , 1994, The Indian journal of medical research.
[54] C. Raghuveer,et al. Clinical study of 100 cases of Kyasanur Forest disease with clinicopathological correlation. , 1993, Indian journal of medical sciences.
[55] H. Feldmann,et al. Replication of Marburg virus in human endothelial cells. A possible mechanism for the development of viral hemorrhagic disease. , 1993, The Journal of clinical investigation.
[56] Krivenchuk Na,et al. The effect of the methods for producing an experimental Marburg virus infection on the characteristics of the course of the disease in green monkeys , 1992 .
[57] P. Jahrling,et al. Combined simian hemorrhagic fever and Ebola virus infection in cynomolgus monkeys. , 1992, Laboratory animal science.
[58] J. Maiztegui,et al. A plasma inhibitor of platelet aggregation in patients with Argentine hemorrhagic fever. , 1989, The American journal of tropical medicine and hygiene.
[59] J. Huggins. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. , 1989, Reviews of infectious diseases.
[60] C. Peters,et al. Hemostatic derangement produced by Rift Valley fever virus in rhesus monkeys. , 1989, Reviews of infectious diseases.
[61] C. Peters,et al. Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha. , 1989, Reviews of infectious diseases.
[62] J. Leduc. Epidemiology of hemorrhagic fever viruses. , 1989, Reviews of infectious diseases.
[63] J. Gear. Clinical aspects of African viral hemorrhagic fevers. , 1989, Reviews of infectious diseases.
[64] J. Frame. Clinical features of Lassa fever in Liberia. , 1989, Reviews of infectious diseases.
[65] K. Pavri. Clinical, clinicopathologic, and hematologic features of Kyasanur Forest disease. , 1989, Reviews of infectious diseases.
[66] M. Turell,et al. Vector potential of selected North American mosquito species for Rift Valley fever virus. , 1988, The American journal of tropical medicine and hygiene.
[67] J. McCormick,et al. A case-control study of the clinical diagnosis and course of Lassa fever. , 1987, The Journal of infectious diseases.
[68] C. Peters,et al. Effect of ribavirin and tributylribavirin on argentine hemorrhagic fever (Junin virus) in guinea pigs , 1986, Antimicrobial Agents and Chemotherapy.
[69] C. Peters,et al. Rift Valley fever virus vaccine trial: study of neutralizing antibody response in humans. , 1985, Vaccine.
[70] J. Maiztegui,et al. IMPORTANCE OF DOSE OF NEUTRALISING ANTIBODIES IN TREATMENT OF ARGENTINE HAEMORRHAGIC FEVER WITH IMMUNE PLASMA , 1984, The Lancet.
[71] B. Simmons,et al. Guideline for isolation precautions in hospitals , 1984, American Journal of Infection Control.
[72] M. Weissenbacher,et al. Protection against a pathogenic strain of Junin virus by mucosal infection with an attenuated strain. , 1983, The American journal of tropical medicine and hygiene.
[73] W. Gransden,et al. A case of Lassa fever: experience at St Thomas's Hospital. , 1982, British medical journal.
[74] K. Johnson,et al. MARBURG-VIRUS DISEASE IN KENYA , 1982, The Lancet.
[75] C. B. Cropp,et al. Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues. , 1981, The American journal of tropical medicine and hygiene.
[76] P. Jahrling,et al. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. , 1980, The Journal of infectious diseases.
[77] J. Maiztegui,et al. EFFICACY OF IMMUNE PLASMA IN TREATMENT OF ARGENTINE HÆMORRHAGIC FEVER AND ASSOCIATION BETWEEN TREATMENT AND A LATE NEUROLOGICAL SYNDROME , 1979, The Lancet.
[78] S. Halstead. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. , 1979, The Journal of infectious diseases.
[79] H. Hoogstraal,et al. An epizootic of Rift Valley fever in Egypt in 1977 , 1979, Veterinary Record.
[80] K. Banerjee,et al. Viral infections in laboratory persnnel. , 1979, The Indian journal of medical research.
[81] K. Johnson,et al. Lassa fever: response to an imported case. , 1977, The New England journal of medicine.
[82] G. Lloyd,et al. A case of Ebola virus infection. , 1977, British medical journal.
[83] H. Gilles,et al. Lassa fever in Panguma Hospital, Sierra Leone, 1973-6. , 1977, British medical journal.
[84] B. S. Kuming,et al. Uveal involvement in Marburg virus disease. , 1977, The British journal of ophthalmology.
[85] T. Bothwell,et al. Outbreake of Marburg virus disease in Johannesburg. , 1975, British medical journal.
[86] T. Monath,et al. Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. II. Clinical observations and virological studies on selected hospital cases. , 1974, The American journal of tropical medicine and hygiene.
[87] C. Peters,et al. Hemorrhagic fever in Cochabamba, Bolivia, 1971. , 1974, American journal of epidemiology.
[88] T. Monath,et al. Clinical presentation of Lassa fever cases during the hospital epidemic at Zorzor, Liberia, March-April 1972. , 1973, The American journal of tropical medicine and hygiene.
[89] T. Monath,et al. A hospital epidemic of Lassa fever in Zorzor, Liberia, March-April 1972. , 1973, The American journal of tropical medicine and hygiene.
[90] H. Bourne,et al. Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease. , 1970, The American journal of tropical medicine and hygiene.
[91] J. Casals,et al. Lassa fever, a new virus disease of man from West Africa. 3. Isolation and characterization of the virus. , 1970, The American journal of tropical medicine and hygiene.
[92] J. Frame,et al. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. , 1970, The American journal of tropical medicine and hygiene.
[93] E. Helm,et al. [On an infectious disease transmitted by Cercopithecus aethiops. ("Green monkey disease")]. , 1968, Deutsche medizinische Wochenschrift.
[94] K. Johnson,et al. Chronic Infection of Rodents by Machupo Virus , 1965, Science.
[95] K. C. Smithburn,et al. Rift Valley fever; accidental infections among laboratory workers. , 1949, Journal of immunology.
[96] J. Hudson,et al. RIFT VALLEY FEVER. , 1932 .
[97] Dawn Foster,et al. Smallpox as a biological weapon: implications for the critical care clinician. , 2003, Dimensions of critical care nursing : DCCN.
[98] F. Kaducu,et al. Outbreak of Ebola hemorrhagic fever Uganda, August 2000-January 2001. , 2001, MMWR. Morbidity and mortality weekly report.
[99] B G Iversen,et al. [Anthrax as biological weapon]. , 2001, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.
[100] M. Borchert,et al. Ebola haemorrhagic fever--a review. , 2000, The Journal of infection.
[101] W. Slenczka. The Marburg virus outbreak of 1967 and subsequent episodes. , 1999, Current topics in microbiology and immunology.
[102] C. Peters,et al. Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. , 1999, Annual review of medicine.
[103] Ken Alibek,et al. Biohazard: The Chilling True Story of the Largest Covert Biological Weapons Program in the World--Told from the Inside by the Man Who Ran It , 1999 .
[104] H. Feldmann,et al. The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis. , 1999, Archives of virology. Supplementum.
[105] A. Brunt,et al. Virus Taxonomy. Seventh Report of the International Committee on Taxomony of Viruses , 1999 .
[106] Slenczka Wg. The Marburg virus outbreak of 1967 and subsequent episodes. , 1999 .
[107] P. Jahrling,et al. Patients infected with high-hazard viruses: scientific basis for infection control. , 1996, Archives of virology. Supplementum.
[108] J. Garner,et al. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. , 1996, Infection control and hospital epidemiology.
[109] A. N. Sergeev,et al. [Certain pathogenetic characteristics of a disease in monkeys in infected with the Marburg virus by an airborne route]. , 1995, Voprosy virusologii.
[110] Update: management of patients with suspected viral hemorrhagic fever--United States. , 1995, MMWR. Morbidity and mortality weekly report.
[111] Re-emergence of Bolivian hemorrhagic fever. , 1994, Epidemiological bulletin.
[112] J. Maiztegui,et al. Antiviral treatment of Argentine hemorrhagic fever. , 1994, Antiviral research.
[113] A. Kuehne,et al. Candid No. 1 Argentine hemorrhagic fever vaccine protects against lethal Junin virus challenge in rhesus macaques. , 1992, Intervirology.
[114] C. Peters,et al. Aerosol infection of rhesus macaques with Junin virus. , 1992, Intervirology.
[115] V. Spiridonov,et al. [The effect of the methods for producing an experimental Marburg virus infection on the characteristics of the course of the disease in green monkeys]. , 1992, Voprosy virusologii.
[116] T. Ksiazek,et al. Analytical study of a Rift Valley fever epidemic. , 1989, Research in virology.
[117] A. Shepherd,et al. Epidemiologic and clinical features of Crimean-Congo hemorrhagic fever in southern Africa. , 1987, The American journal of tropical medicine and hygiene.
[118] J. McCormick,et al. Lassa fever. Effective therapy with ribavirin. , 1986, The New England journal of medicine.
[119] J. Frame,et al. The use of Lassa fever convalescent plasma in Nigeria. , 1984, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[120] P. Jahrling,et al. Endemic Lassa fever in Liberia. I. Clinical and epidemiological aspects at Curran Lutheran Hospital, Zorzor, Liberia. , 1984, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[121] E. Stephenson,et al. Effect of environmental factors on aerosol‐induced lassa virus infection , 1984, Journal of medical virology.
[122] W. Emmett Barkley,et al. Biosafety in microbiological and biomedical laboratories , 1984 .
[123] R. Belshe. Textbook of human virology , 1984 .
[124] J. McCormick,et al. Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread. , 1983, Bulletin of the World Health Organization.
[125] B. Niklasson. Rift Valley fever virus vaccine trial: study of side-effects in humans. , 1982, Scandinavian journal of infectious diseases.
[126] J. Meegan. The Rift Valley fever epizootic in Egypt 1977-78. 1. Description of the epizzotic and virological studies. , 1979, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[127] D. Morens,et al. Epidemic Rift Valley fever in Egypt: observations of the spectrum of human illness. , 1979, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[128] John E. Bennett,et al. Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .
[129] L. Strausbaugh,et al. Clinical studies on Rift Valley fever, Part I: Acute febrile and hemorrhagic-like diseases. , 1978, Journal of Egyptian Public Health Association.
[130] J. Gear. Haemorrhagic fevers of Africa: an account of two recent outbreaks. , 1977, Journal of the South African Veterinary Association.
[131] Clayton Aj. Lassa immune serum. , 1977 .
[132] H. A. White. Lassa fever. A study of 23 hospital cases. , 1972, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[133] B. Henderson,et al. Lassa fever. Epidemiological aspects of the 1970 epidemic, Jos, Nigeria. , 1972, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[134] D. Simpson. Marburg agent disease: in monkeys. , 1969, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[135] R. Siegert,et al. The pathogenesis and epidemiology of the "Marburg-virus" infection. , 1969, German medical monthly.
[136] K. Johnson,et al. Isolation of Machupo virus from wild rodent Calomys callosus. , 1966, The American journal of tropical medicine and hygiene.